evidencegaps
Primary study · included by 1 review

Neoadjuvant sintilimab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, phase 2 trial.

Zhang 2022 · Zhang Zhi, Ye Jinjun, Li Hui, et al. · Frontiers in immunology · 2022

Included by

The Efficacy and Safety of Neoadjuvant Immunotherapy in Pan-Squamous Cell Carcinomas: A Meta-Analysis of Esophageal, Head and Neck, Cervical, Lung, Cutaneous, and Oral Squamous Cell Carcinomas.
Non-Cochrane · intervention · 2026 · cited as Zhang 2022 · Supplementary Table S1; reference list

The review does not say which of its outcomes this study informs.

1 including review in total.